Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect of Avadomide (CC-122) in Healthy Males
NCT02049528Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2014
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of avadomide in diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and solid tumor (3 arms), sponsored by Celgene Corporation. Primary endpoints: Area Under the Curve up to 21 days, Maximum Plasma Concentration up to 21 days and 4 more. Started Jan 2014; status: completed.
02
Drugs
avadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)multiple myeloma (MM)solid tumor
Beyond the preview
Go deeper on NCT02049528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049528.